Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice

Bruton tyrosine kinase (BTK) inhibitors represent an important therapeutic advancement for B cell malignancies. Ibrutinib, the first-in-class BTK inhibitor, is approved by the US FDA to treat patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and mantle cell lymphoma...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Brien, Susan M., Brown, Jennifer R., Byrd, John C., Furman, Richard R., Ghia, Paolo, Sharman, Jeff P., Wierda, William G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630614/
https://www.ncbi.nlm.nih.gov/pubmed/34858810
http://dx.doi.org/10.3389/fonc.2021.720704

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630614/
https://www.ncbi.nlm.nih.gov/pubmed/34858810
http://dx.doi.org/10.3389/fonc.2021.720704

Ejemplares similares